Cargando…

Suppression of BRCA1 sensitizes cells to proteasome inhibitors

BRCA1 is a multifunctional protein best known for its role in DNA repair and association with breast and ovarian cancers. To uncover novel biologically significant molecular functions of BRCA1, we tested a panel of 198 approved and experimental drugs to inhibit growth of MDA-MB-231 breast cancer cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Y, Bouwman, P, Greco, D, Saarela, J, Yadav, B, Jonkers, J, Kuznetsov, S G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649846/ https://www.ncbi.nlm.nih.gov/pubmed/25522274 http://dx.doi.org/10.1038/cddis.2014.537

Ejemplares similares

BRCA1-deficient breast cancer cell lines are resistant to MEK inhibitors and show distinct sensitivities to 6-thioguanine
por: Gu, Yuexi, et al.
Publicado: (2016)

BRCA1 and CtIP promote alternative non-homologous end-joining at uncapped telomeres
por: Badie, Sophie, et al.
Publicado: (2015)

Suppression of the Oncogenic Transcription Factor FOXM1 by Proteasome Inhibitors
por: Gartel, Andrei L.
Publicado: (2014)

Mitochondrial DNA depletion sensitizes cancer cells to PARP inhibitors by translational and post-translational repression of BRCA2
por: Arbini, A A, et al.
Publicado: (2013)

Preclinical mouse models for BRCA1-associated breast cancer
por: Drost, R M, et al.
Publicado: (2009)

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
por: Bouwman, Peter, et al.
Publicado: (2010)

BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity
por: Tacconi, Eliana MC, et al.
Publicado: (2017)

The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells
por: Barazas, Marco, et al.
Publicado: (2018)

Prediction of the functional impact of missense variants in BRCA1 and BRCA2 with BRCA-ML
por: Hart, Steven N., et al.
Publicado: (2020)

BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A
por: Puppe, Julian, et al.
Publicado: (2009)

The PARP-1 inhibitor Olaparib suppresses BRCA1 protein levels, increases apoptosis and causes radiation hypersensitivity in BRCA1(+/-) lymphoblastoid cells
por: Bourton, Emma C., et al.
Publicado: (2017)

The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma
por: Vdovin, Alexander, et al.
Publicado: (2022)

Novel proteasome inhibitor ixazomib sensitizes neuroblastoma cells to doxorubicin treatment
por: Li, Haoyu, et al.
Publicado: (2016)

The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-β1
por: Zeniya, Moko, et al.
Publicado: (2017)

Upregulation of Protein Synthesis and Proteasome Degradation Confers Sensitivity to Proteasome Inhibitor Bortezomib in Myc-Atypical Teratoid/Rhabdoid Tumors
por: Tran, Huy Minh, et al.
Publicado: (2020)

BRCA1 and TP53 codeficiency causes a PARP inhibitor–sensitive erythroproliferative neoplasm
por: Lopez-Perez, Gerardo, et al.
Publicado: (2022)

Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
por: Acosta-Alvear, Diego, et al.
Publicado: (2015)

Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models
por: Crawford, L J, et al.
Publicado: (2014)

Proteasome inhibitors in glioblastoma
por: Huang, Wen-Juan, et al.
Publicado: (2017)

Proteasome inhibitors in glioblastoma
por: Huang, Wen-Juan, et al.
Publicado: (2017)

The capture proteasome assay (CAPA) to evaluate subtype-specific proteasome inhibitors
por: Vigneron, Nathalie, et al.
Publicado: (2015)

BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts
por: Lohse, I, et al.
Publicado: (2015)

A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases
por: Liu, Ningning, et al.
Publicado: (2014)

Restoring MLL reactivates latent tumor suppression-mediated vulnerability to proteasome inhibitors
por: Ge, Maolin, et al.
Publicado: (2020)

BRCA2 Acts as RAD51 Loader to Facilitate Telomere Replication and Capping
por: Badie, Sophie, et al.
Publicado: (2010)

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
por: Hodgson, Darren R., et al.
Publicado: (2018)

Cooperation between BRCA1 and vitamin D is critical for histone acetylation of the p21waf1 promoter and for growth inhibition of breast cancer cells and cancer stem-like cells
por: Pickholtz, Itay, et al.
Publicado: (2014)

Targeting BRCA1 and BRCA2 Deficiencies with G-Quadruplex-Interacting Compounds
por: Zimmer, Jutta, et al.
Publicado: (2016)

MiR-200c Regulates Noxa Expression and Sensitivity to Proteasomal Inhibitors
por: Lerner, Mikael, et al.
Publicado: (2012)

The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis
por: van Dijk, Marianne, et al.
Publicado: (2011)

Evaluation of BRCA1 and BRCA2 as Indicators of Response to Immune Checkpoint Inhibitors
por: Zhou, Zhijun, et al.
Publicado: (2021)

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma
por: Gu, Yanyan, et al.
Publicado: (2020)

An unstructured proteasome inhibitor comes into focus
por: Nemec, Antonia A., et al.
Publicado: (2023)

Arabidopsis PROTEASOME REGULATOR1 is required for auxin-mediated suppression of proteasome activity and regulates auxin signalling
por: Yang, Bao-Jun, et al.
Publicado: (2016)

Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism
por: Wang, Jinhai, et al.
Publicado: (2021)

Proteasome Dysfunction Leads to Suppression of the Hypoxic Response Pathway in Arabidopsis
por: Xia, Xue, et al.
Publicado: (2022)

ATRT-01. UPREGULATION OF PROTEIN SYNTHESIS AND PROTEASOME DEGRADATION CONFERS SENSITIVITY TO PROTEASOME INHIBITOR BORTEZOMIB IN MYC-ATYPICAL TERATOID/RHABDOID TUMORS
por: Tran, Minh-Huy, et al.
Publicado: (2020)

BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival
por: Gorrini, Chiara, et al.
Publicado: (2013)

Site-Specific Proteasome Inhibitors
por: Kisselev, Alexei F.
Publicado: (2021)

Inhibition of IRE1α RNase activity sensitizes patient‐derived acute myeloid leukaemia cells to proteasome inhibitors
por: Creedican, Stuart, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7ndsm8flabt5lfc0f5a6spola2